A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

Inclusion Criteria:

• Diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening

• Confirmed diagnosis of moderate-to-severe CD

• History of prior exposure to standard treatment (5-Amino Salicylates (5-ASAs),steroids, immunomodulators or antibiotics) or advanced therapies (ATs) (biologics orsmall molecules), but having inadequate response to, loss or response to orintolerance to at least one of these therapies

• On stable doses of standard treatments prior to screening (Oral 5-ASA compounds,Oral corticosteroids, Azathioprine (AZA), 6-Mercaptopurine (6-MP), or Methotrexate (MTX), or Antibiotics, etc.)

• Contraceptive use by men and women should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies

Exclusion Criteria:

• Participants with active Ulcerative Colitis (UC), indeterminate colitis, adenomatouscolonic polyps not excised, colonic mucosal dysplasia (low- or high-grade dysplasia)or short bowel syndrome

• Participants with CD isolated to the stomach, duodenum, jejunum, or perianal region,without colonic or ileal involvement

• Participants with following ongoing known complications of CD:

• Any manifestation that might require bowel surgery while enrolled in the study

• Participant with ostomy or ileoanal pouch

• Participant diagnosed with conditions that could interfere with drug absorptionincluding but not limited to short bowel syndrome

• Participant with surgical bowel resection within the past three months prior toscreening, or a history of >3 bowel resections

• History of any other condition which, in the opinion of the Investigator, would putthe participant at risk by participation in the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.